

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
08 December 2022 (08.12.2022)



(10) International Publication Number
WO 2022/256540 A1

(51) International Patent Classification:

A61K 31/4174 (2006.01) A61K 31/4439 (2006.01)
A61P 3/00 (2006.01)

(21) International Application Number:

PCT/US2022/031977

(22) International Filing Date:

02 June 2022 (02.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/196,013 02 June 2021 (02.06.2021) US
63/196,826 04 June 2021 (04.06.2021) US

(71) Applicants: **ASTELLAS PHARMA INC.** [JP/JP]; 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8411 (JP). **MITOBRIDGE, INC.** [US/US]; 1030 Massachusetts Avenue, Suite 200, Cambridge, MA 02138 (US).

(72) Inventors: **KANEMITSU, Naotoshi**; c/o Astellas Pharma Inc., 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8411 (JP). **ITO, Mototsugu**; c/o astellas Pharma Inc., 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8411 (JP). **MULLIGAN, George**; c/o mitobridge Inc., 1030 Massachusetts Avenue, Suite 200, Cambridge, MA 02138 (US). **TAKAE, Seiji**; c/o astellas Pharma Inc., 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8411 (JP). **TANAKA, Marina**; c/o astellas Pharma Inc., 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8411 (JP).

(74) Agent: **DAVIS, Steven G.** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: METHODS OF USE OF PPAR AGONIST COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF



(57) Abstract: The present disclosure relates to methods of use of an agonist of peroxisome proliferator-activated receptors delta (PPAR δ) (e.g., Compound (I) or a pharmaceutically acceptable salt thereof disclosed herein), for example, for treating patients having primary mitochondrial myopathies (PMM). The present disclosure also relates to a pharmaceutical composition comprising an agonist of peroxisome proliferator-activated receptors delta (PPAR δ) and croscarmellose sodium.